Skip to content

Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, bought INBX on Sep 28, 2026

Data as of Oct 16

▲ BUY$148K1,500 shares at $98.88Mark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.
Watch INBX
Traded
Sep 28, 2026
Disclosed
Sep 28, 2026
Filed
The same day

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, bought INBX on Sep 28, 2026TRADEDDISCLOSED
INBXSimilar stocks (XLV — its sector index fund), rebased to INBX's price on the disclosure day
INBX since disclosure
−11.7%
Similar stocks (XLV) since disclosure
+3.2%
XLV — its sector index fund

Change in closing price from Sep 28, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$305Kdisclosed Sep 28 · filed the same day
  2. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$217Kdisclosed Sep 28 · filed 3 days after the trade
  3. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$329Kdisclosed Sep 28 · filed 3 days after the trade

See every trade on INBX →